Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination drug product containing three active ingredients: - **Antibiotics** (class of drugs used to treat bacterial infections; specific antibiotic not specified) - **Levocetirizine** (a second-generation antihistamine that selectively inhibits peripheral H1 receptors, reducing symptoms of allergic rhinitis and urticaria by blocking the action of histamine[6][8][9]) - **Oxymetazoline** (a topical nasal decongestant that acts as an alpha-1A adrenoceptor agonist, causing vasoconstriction in the nasal mucosa to relieve congestion[2][7]) The combination is likely intended for symptomatic relief in upper respiratory tract infections or allergic conditions where both infection and allergy symptoms are present, such as acute rhinosinusitis or severe allergic rhinitis with secondary bacterial infection. The precise mechanism will depend on the specific antibiotic included.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on antibiotics + levocetirizine + oxymetazoline.